UltraScan™ 650 Bone Densitometer
The only FDA-approved bone sonometer to measure BMD
The UltraScan™ 650 is the first and only FDA-approved bone sonometer that measures bone mineral density (BMD), the most important factor in determining the risk of osteoporotic fracture. Conventional bone sonometers measure parameters like SOS and/or BUA. These parameters have poor correlation with BMD, usually less than 0.8, and thus these devices perform poorly in terms of identifying those individuals with osteoporosis. By contrast, the UltraScan™ 650 uses novel patented net time delay (NTD) technology which allows measurement of the quantity of bone, which in turn provides a direct evaluation of BMD. Clinical studies on the UltraScan™ 650 show that its output, BMDUS, is highly correlated (r = 0.931) with x-ray based (DXA) measures of BMD. DXA-BMD has‒‒until now that is‒‒been the “gold standard” for bone assessment. Now, with the availability of the UltraScan™ 650, BMD can be measured without the need for DXA, without the ionizing radiation of x-rays, at lower cost and in less time. Download a brochure on the UltraScan 650, and please Contact Us for more information or to place an order for an UltraScan™ 650, a next generation bone densitometer.
1It should be noted that the correlation of forearm BMD values as determined by DXA machines from different manufacturers is usually in the range of 0.8 to 0.95.